HLA-A and sarcoma: Afami-cel (Afamitresgene autoleucel, marketed as Tecelra) targeting MAGE-A4/HLA-A*02:01 in patients with sarcoma (11) and Tebentafusp, a TCR-derived bispecific receptor recognizing gp100/HLA-A*02:01 and CD3 approved for uveal melanoma are prominent examples (12).